<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217904</url>
  </required_header>
  <id_info>
    <org_study_id>8591-003</org_study_id>
    <secondary_id>2014-002192-28</secondary_id>
    <nct_id>NCT02217904</nct_id>
  </id_info>
  <brief_title>A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)</brief_title>
  <official_title>A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8591 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral
      therapy (ART) activity of MK-8591 monotherapy in ART-naive, human immunodeficiency virus-1
      (HIV-1) infected participants. The primary hypothesis is that at a safe and tolerable dose of
      MK-8591, the true mean difference in the plasma HIV-1 ribonucleic acid (RNA) reduction from
      baseline between MK-8591 and placebo is at least 0.5 log (base10) copies/mL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">May 11, 2017</completion_date>
  <primary_completion_date type="Actual">May 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma HIV-1 RNA</measure>
    <time_frame>Baseline and 168 hours (7 days) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with one or more adverse events</measure>
    <time_frame>Up to 21 days postdose</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>MK-8591 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of MK-8591 0.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 30 mg Extended Observation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 30 mg MK-8591 administered following &gt;8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg MK-8591</intervention_name>
    <description>Single oral dose of 1 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg MK-8591</intervention_name>
    <description>Single oral dose of 2 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg MK-8591</intervention_name>
    <description>Single oral dose of 10 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg MK-8591</intervention_name>
    <description>Single oral dose of 30 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 30 mg</arm_group_label>
    <arm_group_label>MK-8591 30 mg Extended Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg MK-8591</intervention_name>
    <description>Single oral dose of 0.5 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25 mg MK-8591</intervention_name>
    <description>Single oral dose of 0.25 mg MK-8591 administered following ≥8 hour fast</description>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant, non-breast feeding, postmenopausal or surgically sterile female

          -  Female with reproductive potential agrees to use (or have male partner use) two
             acceptable methods of birth control

          -  Male agrees to use acceptable method of contraception during study and for 90 days
             after last dose of trial drug

          -  Has stable baseline health, other than HIV infection

          -  Has no significantly abnormal electrocardiogram

          -  Is HIV-1 positive

          -  Have a screening plasma HIV-1 RNA ≥ 10,000 copies/mL within 30 days prior to the
             treatment phase of this study. For inclusion in Panel MK-8591 Extended Observation,
             participants must also have a screening plasma HIV-1 RNA ≤ 25,000 copies/mL within 30
             days prior to the treatment phase.

          -  Is ART naive

          -  Has not received any investigational agent or marketed ART within 30 days of trial
             drug administration

          -  Is diagnosed with HIV-1 infection &gt;= 3 months prior to screening

          -  Is willing to receive no other ART during treatment phase of study

          -  Has no evidence of mutations conferring resistance to nucleoside reverse transcriptase
             inhibitors (NRTIs)

        Exclusion Criteria:

          -  Is mentally or legally institutionalized/incapacitated, or has significant emotional
             problems, or has a history of clinically significant psychiatric disorder of the last
             5 years

          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological (outside of HIV-1 infection), renal,
             respiratory, genitourinary, major neurological abnormalities or diseases

          -  Has a history of cancer (malignancy)

          -  Has a history of significant multiple and/or severe allergies, or had an anaphylactic
             reaction to drugs or food

          -  Is positive for hepatitis B surface antigen

          -  Has a history of chronic Hepatitis C

          -  Had major surgery or lost 500 mL of blood with 4 weeks prior to screening visit

          -  Has participated in another investigational trial within 4 weeks prior to dosing visit

          -  Will use any medications, prescribed drugs, or herbal remedies 4 weeks prior to dosing
             of trial drug, up to the post-trial visit

          -  Consumes excessive amounts of alcohol, caffeinated beverages, or tobacco products

          -  Uses illicit drugs or has a history of drug abuse within the prior 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>August 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>May 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

